Acrivon Therapeutics, Inc. (ACRV)
ACRVNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$1.58
+0.0054 (+0.34%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $1.65 +5.10%
- Market cap
- $70.71m
- P/E
- –
- EPS, last 4 quarters
- $-1.88
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.27 to $3.56
- Average volume
- –
- Previous close
- $1.57
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $10.50, +566.5% from here
Earnings
next estimate $-0.4400Next report
Sep 2025
+17.5%
Dec 2025
0.0%
Mar 2026
0.0%
Jun 2026
+12.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$19.69m | -$20.12m | -$19.90m | -$18.67m |
| Net income | -$18.23m | -$18.98m | -$19.04m | -$17.96m |
News
8 latest- Acrivon Therapeutics, Inc. Acquires Oral JAK1 Inhibitor ACR-525 and PKCθ Preclinical Program from Aqilion ABFintel · 6 days ago
- What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy StockZacks · Sep 15, 2026
- Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?Zacks · Sep 3, 2026
- Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to BuyZacks · Aug 24, 2026
- Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's WhyZacks · Mar 3, 2026
- Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances RTTNews · Jan 9, 2026
- Acrivon Stock Sinks 29% Despite Positive Phase 2b Endometrial Cancer Data RTTNews · Jan 8, 2026
- Acrivon's ACR-368 Shows 52% Response Rate In Endometrial Cancer, Expands Trial To Europe RTTNews · Jan 8, 2026
The company
Acrivon is a clinical-stage biopharmaceutical company discovering and developing precision medicines utilizing its proprietary Generative AI-driven, Phosphoproteomics AP3 platform. The platform allows the company to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. The AP3 platform is comprised of a growing suite of powerful, internally-developed tools, including the AP3 Data Portal, converting multimodal data into structured data for generative AI analyses, including the AP3 Kinase Substrate Relationship Predictor and the AP3 Interactome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- acrivon.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.